Lenvatinib
Lua error in Module:Infobox at line 314: malformed pattern (missing ']'). Lenvatinib (E7080; trade name Lenvima) is a multi-kinase inhibitor developed by Eisai Co. It inhibits both VEGFR2 and VEGFR3 kinases.[1]
Lenvatinib was granted orphan drug status for the treatment of various types of thyroid cancer that do not respond to radioiodine in the US and Japan in 2012 and in Europe in 2013.[2]
In February 2015, the FDA granted approval to lenvatinib for treatment of progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).[3] In May 2015, EMA granted approval to lenvatinib for the same indication.[4]
Clinical trials
A phase I clinical trial was performed in 2006.[5] A phase III trial started in March 2011.[6]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. [1]
- ↑ European Medicines Agency Summary of the European public assessment report (EPAR) for Lenvima [2]
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Clinical trial number NCT01321554 for "A Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer" at ClinicalTrials.gov
